Comparing Late Toxicity of Conventional versus Hypofractionated Postmastectomy Radiotherapy: Retrospective Analysis

Document Type : Original Article

Authors

1 Clinical Oncology & Nuclear Medicine Department, Faculty of Medicine, Zagazig university

2 Clinical Oncology & Nuclear Medicine Department, Faculty of Medicine, Zagazig university

3 Clinical oncology department, zagazig university, zagazig, egypt

Abstract

Background: Breast cancer (BC) is predicted to be the most common malignancy for Egyptian women, representing 37.7% of all cancers in females and 29.1% of cancer-related mortality. The present work aims to compare the late toxicity of conventional versus hypofractionated postmastectomy radiotherapy.

Methods: This retrospective randomized cross-section investigation was conducted on 154 cases who received hypofractionated (HF) and conventional fractionated (CF) radiotherapy (RT) at the Clinical Oncology Department of Zagazig University Hospitals. Data was obtained from patients' files and follow-up toxicity sheets. The studied cases were divided into Group I: 64 cases received conventional radiotherapy. Group II: 90 cases received hypofractionated radiotherapy.

Results: There was no substantial variance between the studied groups in the number of dissected lymph nodes, frequency, neoadjuvant or adjuvant chemotherapy, frequency of Herceptin intake, or frequency and type of hormonal therapy. There was a remarkable elevation in the degree of skin, subcutaneous, and lung among HF- the postmastectomy RT (HF-PMRT) group compared to the CF-PMRT group. At the same time, Brachial plexopathy showed a statistically significant increase in its degree among the CF-PMRT group compared to the HF-PMRT group.

Conclusion: Our research indicated that HFRT therapy is comparable to CFRT without evidence of inferior local tumor control or increased side effects. It is possible to recommend HFRT as an alternative to HFRT for PM chest wall RT because it is both safe and effective

Keywords

Main Subjects